PIK3CA and breast carcinoma: One mechanism of resistance to trastuzumab is mediated through activation of downstream signaling via the phosphatidylinositol-3 kinase (PI3K)/AKT pathway, which has been identified as a major determinant of trastuzumab resistance in breast cancer [7,8].